Sutro Biopharma, Inc.

DB:S09 Stock Report

Market Cap: €161.5m

Sutro Biopharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bill Newell

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage32.2%
CEO tenure16yrs
CEO ownership0.4%
Management average tenure1.9yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bill Newell's remuneration changed compared to Sutro Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$124m

Jun 30 2024n/an/a

-US$124m

Mar 31 2024n/an/a

-US$115m

Dec 31 2023US$2mUS$687k

-US$107m

Sep 30 2023n/an/a

-US$172m

Jun 30 2023n/an/a

-US$143m

Mar 31 2023n/an/a

-US$130m

Dec 31 2022US$3mUS$663k

-US$119m

Sep 30 2022n/an/a

-US$123m

Jun 30 2022n/an/a

-US$134m

Mar 31 2022n/an/a

-US$114m

Dec 31 2021US$6mUS$625k

-US$106m

Sep 30 2021n/an/a

-US$127m

Jun 30 2021n/an/a

-US$79m

Mar 31 2021n/an/a

-US$43m

Dec 31 2020US$2mUS$554k

-US$32m

Sep 30 2020n/an/a

US$13m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$4mUS$497k

-US$56m

Sep 30 2019n/an/a

-US$42m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$38m

Dec 31 2018US$9mUS$482k

-US$35m

Compensation vs Market: Bill's total compensation ($USD2.13M) is above average for companies of similar size in the German market ($USD837.57K).

Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.

CEO

Bill Newell (66 yo)

16yrs

Tenure

US$2,129,980

Compensation

Mr. William J. Newell, also known as Bill, J.D. has been the Chief Executive Officer and Director of Sutro Biopharma, Inc. since February 2009. He served as Independent Director at Vaxcyte, Inc. since Nove...

Leadership Team

NamePositionTenureCompensationOwnership
William Newell
CEO & Director16yrsUS$2.13m0.41%
€ 659.4k
Hans-Peter Gerber
Chief Scientific Officer1.3yrsUS$1.63m0.029%
€ 47.2k
Anne Borgman-Hagey
Chief Medical Officer1.9yrsUS$2.34m0.030%
€ 47.7k
Jane Chung
President & COO1.2yrsUS$1.43m0.085%
€ 137.7k
James Swartz
Founderno datano datano data
Edward Albini
CFO & Secretary12yrsUS$2.08m0.13%
€ 209.0k
Venkatesh Srinivasan
Chief Technical Operations Officer1.7yrsno data0.038%
€ 62.1k
David Pauling
General Counsel3.8yrsno datano data
Linda Fitzpatrick
Chief People & Communications Officer17yrsUS$1.30m0.10%
€ 163.2k
Barbara Leyman
Chief Business Development Officerless than a yearno datano data
Regina Cheng
Vice President & Controllerno datano datano data

1.9yrs

Average Tenure

62yo

Average Age

Experienced Management: S09's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
William Newell
CEO & Director16yrsUS$2.13m0.41%
€ 659.4k
Connie Matsui
Independent Chair of the Board5.6yrsUS$173.11k0%
€ 0
James Panek
Independent Director5yrsUS$138.11k0%
€ 0
John Freund
Independent Director10.9yrsUS$138.11k0.068%
€ 110.3k
Daniel Petree
Independent Director15.4yrsUS$140.11k0.027%
€ 44.0k
Trevor Hallam
Member of Scientific Advisory Board2yrsUS$1.53m0.12%
€ 196.5k
Carlos Paya
Chair of the Scientific Advisory Board4.7yrsno datano data
Michael Dybbs
Independent Director6.5yrsUS$133.11k0%
€ 0
Joseph Lobacki
Independent Director7.9yrsUS$152.11k0%
€ 0
Lawrence Fong
Co-Chair of Clinical Advisory Board & Member of Scientific Advisory Boardno datano datano data
Lainie Martin
Member of the Clinical Advisory Board4.7yrsno datano data
Heidi Hunter
Independent Director3.2yrsUS$150.28k0%
€ 0

5.6yrs

Average Tenure

66yo

Average Age

Experienced Board: S09's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 03:29
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sutro Biopharma, Inc. is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Tazeen AhmadBofA Global Research
Thomas ShraderBTIG